Cover Image
市場調查報告書

子宮內膜異位症:開發中產品分析

Endometriosis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232822
出版日期 內容資訊 英文 128 Pages
訂單完成後即時交付
價格
Back to Top
子宮內膜異位症:開發中產品分析 Endometriosis - Pipeline Review, H1 2017
出版日期: 2017年05月09日 內容資訊: 英文 128 Pages
簡介

所謂子宮內膜異位通常是子宮內部的組織(子宮內膜)擴大到子宮外部這樣的疾病,常會伴隨疼痛。主要症狀有骨盤痛及月經痙攣、發炎、不孕症、異常出血等。致病因子有排尿不順、骨盤內感染症病歷、家族病史等。主要治療藥有非甾體抗炎藥物(NSAID)和口服避孕藥,黃體激素物質等。

本報告提供全球各國治療子宮內膜異位症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

子宮內膜異位症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

子宮內膜異位症:企業開發中的治療藥

子宮內膜異位症:大學/機關研究中的治療藥

子宮內膜異位症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

子宮內膜異位症:企業開發中的產品

子宮內膜異位症:大學/機關研究中的產品

子宮內膜異位症的治療藥的開發企業

  • AbbVie Inc.
  • Addex Therapeutics Ltd
  • APAvadis Biotechnologies Srl
  • Astellas Pharma Inc.
  • Bayer AG
  • Dongkook Pharmaceutical Co., Ltd.
  • ElexoPharm GmbH
  • EndoCeutics, Inc.
  • Euroscreen S.A.
  • Evotec AG
  • Forendo Pharma Limited
  • GlaxoSmithKline Plc
  • Kissei Pharmaceutical Co., Ltd.
  • Lipicard Technologies Limited
  • 日本新藥
  • Orphagen Pharmaceuticals, Inc.
  • Philogen S.p.A.
  • Repros Therapeutics Inc.
  • SK Chemicals Co., Ltd.
  • 武田藥品工業
  • ValiRx Plc

子宮內膜異位症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

子宮內膜異位症:最近的開發平台趨勢

子宮內膜異位症:暫停中的計劃

子宮內膜異位症:開發中止的產品

子宮內膜異位症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9221IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Pipeline Review, H1 2017, provides an overview of the Endometriosis (Women's Health) pipeline landscape.

Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (the endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. The predisposing factors uterine abnormalities, History of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometriosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Endometriosis (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometriosis (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 8, 6, 1, 17, 7 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 3 molecules, respectively.

Endometriosis (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Endometriosis (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Endometriosis (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Endometriosis (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Endometriosis (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Endometriosis (Women's Health)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Endometriosis (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Endometriosis (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Endometriosis - Overview
    • Endometriosis - Therapeutics Development
  • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Endometriosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Endometriosis - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Addex Therapeutics Ltd
    • APAvadis Biotechnologies Srl
    • Astellas Pharma Inc
    • Bayer AG
    • Dongkook Pharmaceutical Co Ltd
    • ElexoPharm GmbH
    • EndoCeutics Inc
    • Enteris BioPharma Inc
    • Evotec AG
    • Forendo Pharma Ltd
    • Kissei Pharmaceutical Co Ltd
    • Lipicard Technologies Ltd
    • Luye Pharma Group Ltd
    • Nippon Shinyaku Co Ltd
    • Ogeda SA
    • Orphagen Pharmaceuticals Inc
    • Philogen SpA
    • Repros Therapeutics Inc
    • SK Chemicals Co Ltd
    • Takeda Pharmaceutical Company Ltd
    • ValiRx Plc
    • Viramal Ltd
  • Endometriosis - Drug Profiles
    • acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile
    • ADX-68692 - Drug Profile
    • ASP-1707 - Drug Profile
    • BAY-1128688 - Drug Profile
    • BAY-1158061 - Drug Profile
    • danazol - Drug Profile
    • Drug 1 for Endometriosis - Drug Profile
    • Drug 2 for Endometriosis - Drug Profile
    • Drug 3 for Endometriosis - Drug Profile
    • Drug 4 for Endometriosis - Drug Profile
    • Drug 5 for Endometriosis - Drug Profile
    • Drug to Antagonize P2X3 for Endometriosis - Drug Profile
    • Drug to Inhibit C-Jun for Endometriosis - Drug Profile
    • Drugs for Endometriosis and Uterine Fibroids - Drug Profile
    • EC-313 - Drug Profile
    • elagolix sodium - Drug Profile
    • EVE-104 - Drug Profile
    • fezolinetant - Drug Profile
    • FP-5677 - Drug Profile
    • goserelin biosimilar - Drug Profile
    • goserelin ER - Drug Profile
    • KLH-2109 - Drug Profile
    • leuprolide acetate - Drug Profile
    • LT-6121 - Drug Profile
    • MIA-602 - Drug Profile
    • NHP-07 - Drug Profile
    • NS-580 - Drug Profile
    • Peptides for Endometriosis and Hepatic Tumor - Drug Profile
    • Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor - Drug Profile
    • PGL-2001 - Drug Profile
    • Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome - Drug Profile
    • relugolix - Drug Profile
    • SKI-2670 - Drug Profile
    • Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile
    • Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile
    • Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile
    • Small Molecules to Antagonize SF-1 for Cushing Disease, Endometriosis and Oncology - Drug Profile
    • Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile
    • Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile
    • Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile
    • Small Molecules to Inhibit HSD17B1 for Endometriosis - Drug Profile
    • SR-16234 - Drug Profile
    • Stem Cell Therapy for Asherman's Syndrome and Endometrial Atrophy - Drug Profile
    • Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
    • telapristone acetate - Drug Profile
    • Tetravil - Drug Profile
    • TOT-206 - Drug Profile
    • triptorelin acetate ER - Drug Profile
    • triptorelin biosimilar - Drug Profile
    • VAL-301 - Drug Profile
    • vilaprisan - Drug Profile
    • VPE-001 - Drug Profile
    • VPEA-004 - Drug Profile
  • Endometriosis - Dormant Projects
  • Endometriosis - Discontinued Products
  • Endometriosis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Endometriosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Endometriosis - Pipeline by AbbVie Inc, H1 2017
  • Endometriosis - Pipeline by Addex Therapeutics Ltd, H1 2017
  • Endometriosis - Pipeline by APAvadis Biotechnologies Srl, H1 2017
  • Endometriosis - Pipeline by Astellas Pharma Inc, H1 2017
  • Endometriosis - Pipeline by Bayer AG, H1 2017
  • Endometriosis - Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017
  • Endometriosis - Pipeline by ElexoPharm GmbH, H1 2017
  • Endometriosis - Pipeline by EndoCeutics Inc, H1 2017
  • Endometriosis - Pipeline by Enteris BioPharma Inc, H1 2017
  • Endometriosis - Pipeline by Evotec AG, H1 2017
  • Endometriosis - Pipeline by Forendo Pharma Ltd, H1 2017
  • Endometriosis - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
  • Endometriosis - Pipeline by Lipicard Technologies Ltd, H1 2017
  • Endometriosis - Pipeline by Luye Pharma Group Ltd, H1 2017
  • Endometriosis - Pipeline by Nippon Shinyaku Co Ltd, H1 2017
  • Endometriosis - Pipeline by Ogeda SA, H1 2017
  • Endometriosis - Pipeline by Orphagen Pharmaceuticals Inc, H1 2017
  • Endometriosis - Pipeline by Philogen SpA, H1 2017
  • Endometriosis - Pipeline by Repros Therapeutics Inc, H1 2017
  • Endometriosis - Pipeline by SK Chemicals Co Ltd, H1 2017
  • Endometriosis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Endometriosis - Pipeline by ValiRx Plc, H1 2017
  • Endometriosis - Pipeline by Viramal Ltd, H1 2017
  • Endometriosis - Dormant Projects, H1 2017
  • Endometriosis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Endometriosis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Endometriosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top